Peptide Research Guides: BPC-157, TB-500, GHK-Cu — Page 3 of 14

Chonluten (Thr-Glu-Asp): Evidence Status and a Corrected Structural Record

Chonluten is a Thr-Glu-Asp tripeptide with no published study naming it. This page sets out what is verifiable, documents a molecular formula correction made to our own catalog, and is explicit about where the evidence stops.

Aug 6, 2026 · 2 min read

chonluten bioregulator khavinson

Ovagen (Glu-Asp-Leu): A Defined Sequence With No Published Study

Glu-Asp-Leu is a catalogued chemical entity with an unambiguous structure — and no published study under the name Ovagen. A page about the difference between a well-defined molecule and a characterised one.

Aug 6, 2026 · 6 min read

ovagen bioregulator khavinson

Vilon Peptide (Lys-Glu): What the Published Research Reports

Vilon is one of the few Khavinson bioregulators with animal studies naming it directly — spontaneous tumour inhibition, lifespan, induced carcinogenesis models and gene expression. A citation-by-citation summary, with the limits stated.

Aug 6, 2026 · 3 min read

vilon bioregulator khavinson

Cartalax (Ala-Glu-Asp): Evidence Status of an Under-Studied Bioregulator

No PubMed-indexed study names Cartalax in its title. This page sets out what is actually established about the tripeptide — structure, family, classification — and is explicit about where the evidence stops.

Aug 6, 2026 · 2 min read

cartalax bioregulator khavinson

Tesamorelin vs Ipamorelin: Receptor, Evidence and Research Design

Tesamorelin and ipamorelin both raise growth hormone, but through different receptors — and their evidence bases are not symmetrical. A side-by-side comparison of mechanism, published trial data, half-life and regulatory status.

Aug 6, 2026 · 9 min read

tesamorelin ipamorelin GHRH

Tesamorelin Dosage: What the Research Literature Reports

Every tesamorelin dosage figure in the peer-reviewed literature comes from trials in one clinical population. This page collects what those named trials reported — amounts, routes, durations and PubMed citations — and is explicit about where no established amount exists.

Aug 6, 2026 · 9 min read

tesamorelin dosage GHRH

Tirzepatide Structure: Dual GIP/GLP-1 Agonist Molecular Architecture

Tirzepatide's molecular architecture — built on non-natural amino acid substitutions, a C20 fatty diacid tether, and strategic receptor bias — represents the structural blueprint that enabled the leap from single to dual and ultimately triple receptor agonism in metabolic peptide research.

Aug 2, 2026 · 12 min read

["molecular architecture" "dual receptor agonism" "GIP receptor"

Pentapeptide-18 (Leuphasyl): Enkephalin-Like Neuromuscular Research

Pentapeptide-18 (Leuphasyl) is an enkephalin-mimetic sequence that appears to modulate catecholamine release at the neuromuscular junction through opioid receptor engagement, and has been studied in combination with acetyl hexapeptide-3 for dual-pathway neuromuscular signal attenuation in cosmetic research models.

Jul 31, 2026 · 12 min read

["Dermal & Cosmetic Peptides" "Neuromuscular Research" "Enkephalin Mimetics"

Nonapeptide-1: Alpha-MSH Antagonism and Melanogenesis Research

Nonapeptide-1 competes directly with alpha-melanocyte-stimulating hormone at the MC1R receptor, blocking the upstream signaling cascade that drives melanogenesis — a mechanism that operates before tyrosinase is ever activated. This article examines the molecular pharmacology, in vitro evidence, and structural contrasts with agonist peptides in the same pathway.

Jul 31, 2026 · 12 min read

["melanogenesis" "MC1R antagonism" "alpha-MSH"

Vialox (Pentapeptide-3V): Postsynaptic Acetylcholine Receptor Research

Vialox (Pentapeptide-3V) has been characterized in cosmetic peptide research as a competitive antagonist at the postsynaptic nicotinic acetylcholine receptor, exhibiting a curare-like mechanism that may transiently reduce neuromuscular signal transmission at the dermal junction. This article examines its molecular target, compares its blocking mode to Syn-Ake and Argireline, and contextualizes it within the broader landscape of dermal peptide research.

Jul 31, 2026 · 12 min read

["dermal peptides" "neuromuscular peptides" "acetylcholine receptor"

Lipopeptides: Fatty Acid Conjugation and Dermal Penetration Research

Fatty acid conjugation transforms hydrophilic peptides into membrane-permeant lipopeptides capable of traversing the stratum corneum — a structural modification that underpins the bioactivity of palmitoyl-prefixed cosmetic actives studied from Matrixyl to Palmitoyl Tetrapeptide-7. This article examines the physicochemical logic, molecular mechanisms, and comparative research behind lipopeptide dermal delivery.

Jul 31, 2026 · 13 min read

["Dermal peptides" "Cosmetic peptides" "Lipopeptide delivery"

Decapeptide-12: Tyrosinase Inhibition and Melanin Regulation Research

Decapeptide-12 has emerged as a mechanistically precise inhibitor of tyrosinase, the rate-limiting enzyme in melanin biosynthesis, demonstrating competitive inhibition kinetics that distinguish it from upstream signaling antagonists in pigmentation research models.

Jul 31, 2026 · 12 min read

["Dermal Peptides" "Pigmentation Research" "Tyrosinase Inhibition"

Research Articles